Topical nasal corticosteroids in the complex treatment of drug rhinitis

January 19, 2022
Specialities :

Patients suffering from drug-induced rhinitis often continue to use vasoconstrictive nasal drugs to eliminate nasal congestion before seeking medical attention, thus exacerbating the course of the disease.

Objective: to investigate the effectiveness of intranasal topical corticosteroids in the treatment of patients with drug-induced rhinitis.

Object and methods of research. The study group consisted of 20 patients who suffered from drug-induced rhinitis for up to 2 years. Patients in this group were prescribed mometasone furoate intranasal spray 2 doses (100 mcg) in each nasal passage once a day in the morning. To facilitate nasal breathing, patients continued to use decongestants diluted in 50% sterile isotonic sodium chloride solution every 4 days. A control group of patients (16 people with drug-induced rhinitis for no more than 2 years) used a similar method of diluting the decongestant, but did not use a topical corticosteroid.

Results. 14 patients of the control group noted the ineffectiveness of the decongestants used on the 2nd, 2 patients — on the 3rd dilution. In the main group, only 2 patients reported ineffectiveness on the 2nd dilution, 14 — on the 3rd and 4 — claimed that after the 3rd dilution they retained the effect of the decongestant, but less pronounced.

Conclusion. The use of topical nasal corticosteroids in the treatment of drug-induced rhinitis can significantly reduce the dose of decongestants, or even completely abandon them.


  • 1. Hünerman T. (1942) Kritisches zur Schnupfentherapie. Deutsche Medizinische Wochenschrift., 68: 580–581. doi:10.1055/s-0028-1120135.
  • 2. Gollоm J. (1944) The problem of nasal medication with particular reference to Privine HCL 0.1%. Can. Med. Assoc. J., 51(2): 123–126.
  • 3. Riechelmann H., Deutschle T., Stuhlmiller A. et al. (2004) Nasal toxicity of benzalkonium chloride. Am. J. Rhinol., 18(5): 291–299.
  • 4. Graf P., Hallen H. (1996) Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays. Laryngoscope, 106 (5 Pt. 1): 605–609.